Re: NIH Halts Large Cardiovascular Inflammation Reduction Trial (CIRT)
|
5
|
Resverlogix Corp.
|
Sep 23, 2018 01:42PM
|
Zenith Licensing Agreement
|
5
|
Resverlogix Corp.
|
Aug 06, 2019 08:40AM
|
ALP Levels Predict Adverse Cardiovascular Outcomes And Cognitive Impairment In High Risk Patients
|
5
|
Resverlogix Corp.
|
Aug 08, 2019 12:39PM
|
Re: And we wait.......
|
5
|
Resverlogix Corp.
|
Jan 24, 2018 07:04AM
|
Re: Resverlogix H2 2018 events
|
5
|
Resverlogix Corp.
|
Nov 03, 2018 05:14PM
|
Re: No love
|
5
|
Resverlogix Corp.
|
Dec 13, 2018 02:35PM
|
Re: Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
|
5
|
Resverlogix Corp.
|
Mar 28, 2018 07:34AM
|
Re: H1 2020 Potential Events
|
5
|
Resverlogix Corp.
|
Mar 09, 2020 02:21PM
|
PFI-1 (aka PF-6405761)
|
5
|
Zenith Epigenetics
|
Jun 26, 2018 02:52PM
|
Re: FDA approves drug that reduces MACE in Diabetes patients (Forbes)
|
5
|
Resverlogix Corp.
|
Jun 14, 2016 07:21AM
|
Constellation Pharma news, courtesy of rndtbl
|
5
|
Zenith Epigenetics
|
Nov 06, 2019 04:06PM
|
Re: New MD&A posted
|
5
|
Resverlogix Corp.
|
Dec 18, 2019 03:18PM
|
Re: ABCA1 overexpression worsens colorectal cancer prognosis and this can be ameliorated by apabetalone
|
5
|
Resverlogix Corp.
|
Aug 14, 2018 11:04AM
|
Going on 5 months since database lock....
|
5
|
Resverlogix Corp.
|
Feb 13, 2020 07:01AM
|
After the dust settles in 3 weeks
|
5
|
Resverlogix Corp.
|
Oct 22, 2015 11:17AM
|
Danny Levine, The Bio Report Interview with Mark Day, Ph.D., President & CEO, Bioasis
|
5
|
BIOASIS TECHNOLOGIES INC
|
Jul 12, 2018 03:15PM
|
Re: NYAS Symposium on Apr 28
|
5
|
Resverlogix Corp.
|
Apr 22, 2016 11:12AM
|
Re: Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on
|
5
|
Resverlogix Corp.
|
Jun 07, 2020 07:28AM
|
Re: Countdown
|
5
|
Resverlogix Corp.
|
Jul 07, 2017 02:03PM
|
Is it just coincidental......
|
5
|
Resverlogix Corp.
|
Oct 13, 2017 03:20PM
|